	US 11,933,785 B2
	Methods for detection, staging, and surveillance of colorectal adenomas and carcinomas
Michael Richard Sussman, Cross Plains, WI (US); Melanie Mae Ivancic, Madison, WI (US); Gregory D Kennedy, Madison, WI (US); William Franklin Dove, Madison, WI (US); Perry Joseph Pickhardt, Madison, WI (US); and Mark Reichelderfer, Madison, WI (US)
Assigned to Wisconsin Alumni Research Foundation, Madison, WI (US)
Appl. No. 16/307,779
Filed by Wisconsin Alumni Research Foundation, Madison, WI (US)
PCT Filed Jun. 12, 2017, PCT No. PCT/US2017/037045 § 371(c)(1), (2) Date Dec. 6, 2018, PCT Pub. No. WO2017/214625, PCT Pub. Date Dec. 14, 2017.
Claims priority of provisional application 62/348,290, filed on Jun. 10, 2016.
Prior Publication US 2019/0302120 A1, Oct. 3, 2019
Int. Cl. G01N 31/00 (2006.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01)

CPC G01N 33/57419 (2013.01) [G01N 2333/4704 (2013.01); G01N 2333/4716 (2013.01); G01N 2333/4728 (2013.01); G01N 2333/4737 (2013.01); G01N 2333/70585 (2013.01); G01N 2333/71 (2013.01); G01N 2333/7456 (2013.01); G01N 2333/81 (2013.01); G01N 2333/90212 (2013.01); G01N 2333/90283 (2013.01); G01N 2800/60 (2013.01)]

13 Claims

1. A method for treating a colorectal cancer patient in need thereof with a neoadjuvant therapy after identifying the patient as having local or regional colorectal cancer, the method comprising:

(a) assaying a biosample from the patient for the plurality of protein biomarkers comprising CD44, C-reactive protein, inter-alpha trypsin inhibitor, heavy chain H3vitamin D binding protein; and dipeptidyl peptidase 4, wherein the protein biomarkers are present in an individual without cancer at reference levels; and

(b) detecting levels of the plurality of the protein biomarkers in the biosample;

wherein the colorectal cancer patient is treated with neoadjuvant therapy when the levels of these protein biomarkers from the patient′ biosample is higher than the reference protein biomarker levels from individuals without colorectal cancer.